{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-005305","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2021-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.844487+00:00","generated_at":"2026-06-27T23:22:36.290633+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcus closes Gilead amendment; receives $725M option fees for 3 programs","bullets":["Closed amendment to Option, License and Collaboration Agreement with Gilead on Dec 21, 2021.","Gilead acquires rights to anti-TIGIT (domvanalimab/AB308), adenosine antagonist (etrumadenant), CD73 (quemliclustat).","Gilead to pay $725 million in option fees, expected early Q1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-005305","json":"https://secwatch.observer/filing/0000950170-21-005305.json","markdown":"https://secwatch.observer/filing/0000950170-21-005305.md","text":"https://secwatch.observer/filing/0000950170-21-005305.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000095017021005305/0000950170-21-005305-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000095017021005305/rcus-20211221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T23:22:36.290633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}